Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction

Starting soon · Not applicable

Conditions studied: Heart Failure With Reduced Ejection Fraction (HFrEF)

In brief

The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure with reduced ejection fraction (HFrEF). The investigators will also determine the effects of EVOO on functional capacity and quality of life.

Key facts

Study ID

NCT07644806

Run by

Old Dominion University

People needed

40

Starts

2026-07-01

Expected to finish

2028-03-31

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with HFrEF with left ventricular ejection fraction ≤35 %.
• Referred to and enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center, but has not yet initiated/started cardiac rehabilitation (i.e., has not attended the first cardiac rehab session).
• Able and willing to comply with study procedures and provide informed consent.

You may not qualify if…

• Co-morbidity expected to limit survival (e.g., terminal illness).
• End-stage renal disease.
• Unstable fluid overload.
• Current pregnancy (self-disclose).
• Habitual use of EVOO greater than 4 tablespoons per day.
• Known allergy or sensitivity to olive oil or its components.
• Unwillingness or inability to incorporate EVOO or dietary recommendations.

Where it is running

• Strelitz Diabetes Center (Williams Hall) — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.